Windtree Completes Enrollment Of Phase 2b Study Of Istaroxime In Early Cardiogenic Shock Caused By Heart Failure
Windtree Completes Enrollment Of Phase 2b Study Of Istaroxime In Early Cardiogenic Shock Caused By Heart Failure
Windtree Therapeutics, Inc. ("Windtree" or the "Company") (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases, today announced it has successfully completed enrollment in its SEISMiC Extension Phase 2b study of istaroxime in early cardiogenic shock caused by heart failure. The study is evaluating the ability of istaroxime to improve heart function and low blood pressure in the setting of early cardiogenic shock due to heart failure. The Company is looking to extend the positive results on these parameters as observed in the Company's first SEISMiC Phase 2 clinical study that was previously reported. In addition, the Company hopes that the study results will substantiate the encouraging observations from the Company's Phase 2 clinical study, indicating istaroxime has a favorable renal profile and does not increase cardiac arrhythmias. The SEISMiC Extension Study is utilizing longer dosing duration and tapering the dosing to assess the potential benefits.
Windtree Therapeutics公司（"Windtree"或"公司") (纳斯达克股票代码: WINT)，一家专注于推进早期和晚期创新治疗方案以应对重要疾病的生物技术公司，今天宣布已成功完成其在早期心原性休克由心力衰竭引起的SEISMiC阶段20亿研究对istaroxime的招募。该研究旨在评估istaroxime在早期心力衰竭引起的心原性休克情况下改善心脏功能和低血压的能力。该公司希望延续此次研究的积极结果，即之前报告的公司首个SEISMiC第2期临床研究中观察到的这些参数的积极结果。此外，公司希望该研究结果将证实公司第2期临床研究中对istaroxime具有有利的肾功能分析，并且不会增加心脏心律失常的鼓舞人心的观察。SEISMiC延伸研究正在利用更长的给药时间和减量给药来评估潜在的好处。
